Evidence map›Paper›PMID 41142333›Full record

ArticleACS central science2025

Enzyme Activity-Based Genome-wide Screening for Modifiers of Lysosomal Glucocerebrosidase Uncovers Candidate Risk Factors for Parkinson's Disease.

Vinod Udayar, Pierre-André Gilormini, Julien Bryois, Alexandra Gehrlein, Xi Chen, Stephanie Sonea, Sha Zhu, Matthew C Deen, Nadia Anastasi, Alan E Murphy and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS central science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Vinod UdayarRoche Pharma Research and Early Development, Neuroscience and Rare Disease Discovery and Translational Area, Roche Innovation Center Basel, 4070 Basel, Switzerland.
Pierre-André GilorminiDepartment of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC V5A 1S6, Canada.ORCID https://orcid.org/0000-0003-1491-1174
Julien BryoisRoche Pharma Research and Early Development, Neuroscience and Rare Disease Discovery and Translational Area, Roche Innovation Center Basel, 4070 Basel, Switzerland.
Alexandra GehrleinRoche Pharma Research and Early Development, Neuroscience and Rare Disease Discovery and Translational Area, Roche Innovation Center Basel, 4070 Basel, Switzerland.
Xi ChenDepartment of Chemistry, Simon Fraser University, Burnaby, BC V5A 1S6 Canada.
Stephanie SoneaDepartment of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC V5A 1S6, Canada.
Sha ZhuDepartment of Chemistry, Simon Fraser University, Burnaby, BC V5A 1S6 Canada.
Matthew C DeenDepartment of Chemistry, Simon Fraser University, Burnaby, BC V5A 1S6 Canada.
Nadia AnastasiRoche Pharma Research and Early Development, Neuroscience and Rare Disease Discovery and Translational Area, Roche Innovation Center Basel, 4070 Basel, Switzerland.
Alan E MurphyUK Dementia Research Institute at Imperial College London, London SW7 2AZ United Kingdom.
Nathan SkeneUK Dementia Research Institute at Imperial College London, London SW7 2AZ United Kingdom.
Manuela M X TanDepartment of Neurology, Oslo University Hospital, Oslo 0424, Norway.
Jon-Anders TunoldDepartment of Neurology, Oslo University Hospital, Oslo 0424, Norway.
Filip RoudnickyRoche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, 4070 Basel, Switzerland.
Wilma D J van de BergDepartment of Anatomy and Neurosciences, Section Clinical Neuroanatomy and Biobanking, Vrije Universiteit Amsterdam, Amsterdam, 1081 HV Netherlands.
Lasse PihlstrømDepartment of Neurology, Oslo University Hospital, Oslo 0424, Norway.
David J VocadloDepartment of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC V5A 1S6, Canada.ORCID https://orcid.org/0000-0001-6897-5558
Ravi JagasiaRoche Pharma Research and Early Development, Neuroscience and Rare Disease Discovery and Translational Area, Roche Innovation Center Basel, 4070 Basel, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mutations in

Identifiers

PMID41142333
PMCPMC12550621

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.